Literature DB >> 1889873

Flucytosine conversion to fluorouracil in humans: does a correlation with gut flora status exist? A report of two cases using fluorine-19 magnetic resonance spectroscopy.

M C Malet-Martino1, R Martino, M de Forni, A Andremont, O Hartmann, J P Armand.   

Abstract

A relationship between the gut flora level, particularly gram-negative enterobacilli, and the in vivo flucytosine conversion to fluorouracil has been observed in humans from the fluorine-19 magnetic resonance spectroscopy analysis of urine from two patients treated with the flucytosine- (6 to 9 g/day) amphotericin B (1 mg/kg/day) combination. Indeed the percentage of fluorouracil metabolites was extremely low (less than 0.6% of total fluorinated compounds excreted) when the number of enterobacillary colonies was low (less than 10(3] and higher (3.5 to 8.8%) when enterobacillary colonies were under reconstitution or in the normal range (10(5) to 10(8]. The intestinal microflora assessment may therefore be of high interest to predict the risk of an additive flucytosine-induced myelotoxicity suspected to be due to fluorouracil during flucytosine chronic therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1889873     DOI: 10.1007/bf01643246

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  9 in total

1.  Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora.

Authors:  B E Harris; B W Manning; T W Federle; R B Diasio
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

Review 2.  Pyrimidine metabolism in microorganisms.

Authors:  G A O'Donovan; J Neuhard
Journal:  Bacteriol Rev       Date:  1970-09

3.  Metabolic studies with 5-fluorocytosine-6-14C in mouse, rat, rabbit, dog and man.

Authors:  A Polak; E Eschenhof; M Fernex; H J Scholer
Journal:  Chemotherapy       Date:  1976       Impact factor: 2.544

Review 4.  The application of nuclear magnetic resonance spectroscopy to drug metabolism studies.

Authors:  M C Malet-Martino; R Martino
Journal:  Xenobiotica       Date:  1989-06       Impact factor: 1.908

5.  Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans: possible factor in 5-fluorocytosine clinical toxicity.

Authors:  R B Diasio; D E Lakings; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

6.  Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis.

Authors:  A M Stamm; R B Diasio; W E Dismukes; S Shadomy; G A Cloud; C A Bowles; G H Karam; A Espinel-Ingroff
Journal:  Am J Med       Date:  1987-08       Impact factor: 4.965

7.  Direct detection of new flucytosine metabolites in human biofluids by 19F nuclear magnetic resonance.

Authors:  J P Vialaneix; M C Malet-Martino; J S Hoffmann; J Pris; R Martino
Journal:  Drug Metab Dispos       Date:  1987 Sep-Oct       Impact factor: 3.922

8.  The metabolism of 5-fluorocytosine-2-14-C and of cytosine-14-C in the rat and the disposition of 5-fluorocytosine-2-14-C in man.

Authors:  B A Koechlin; F Rubio; S Palmer; T Gabriel; R Duschinsky
Journal:  Biochem Pharmacol       Date:  1966-04       Impact factor: 5.858

9.  Identification of minor metabolites of 5-fluorocytosine in man by chemical ionization gas chromatography mass spectrometry.

Authors:  K M Williams; A M Duffield; R K Christopher; P J Finlayson
Journal:  Biomed Mass Spectrom       Date:  1981-04
  9 in total
  7 in total

1.  Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.

Authors:  Annemarie E Brouwer; Hendrikus J M van Kan; Elizabeth Johnson; Adul Rajanuwong; Prapit Teparrukkul; Vannaporn Wuthiekanun; Wirongrong Chierakul; Nick Day; Thomas S Harrison
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

2.  Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy.

Authors:  L D Stegman; A Rehemtulla; B Beattie; E Kievit; T S Lawrence; R G Blasberg; J G Tjuvajev; B D Ross
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

Review 3.  The role of active metabolites in drug toxicity.

Authors:  M Pirmohamed; N R Kitteringham; B K Park
Journal:  Drug Saf       Date:  1994-08       Impact factor: 5.606

Review 4.  Pharmacokinetic optimisation of oral antifungal therapy.

Authors:  M Schäfer-Korting
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

5.  Pharmacokinetics and tolerance of repeated oral administration of 5-fluorocytosine in healthy dogs.

Authors:  Jérémy Béguin; Matthias Kohlhauer; Eve Laloy; Frédérique Degorce; Baptiste Moreau; Éric Quéméneur; Philippe Erbs; Bernard Klonjkowski; Christelle Maurey
Journal:  BMC Vet Res       Date:  2021-06-21       Impact factor: 2.741

6.  Discovery of Bacterial Deaminases That Convert 5-Fluoroisocytosine Into 5-Fluorouracil.

Authors:  Agota Aučynaitė; Rasa Rutkienė; Daiva Tauraitė; Rolandas Meškys; Jaunius Urbonavičius
Journal:  Front Microbiol       Date:  2018-10-08       Impact factor: 5.640

Review 7.  Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal.

Authors:  Angela Loyse; Françoise Dromer; Jeremy Day; Olivier Lortholary; Thomas S Harrison
Journal:  J Antimicrob Chemother       Date:  2013-06-20       Impact factor: 5.790

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.